These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23299288)

  • 21. [Use of simulation models in health economic evaluation studies of dietary salt-reduction policies for cardiovascular disease prevention].
    Kato H; Ikeda N; Sugiyama T; Nomura M; Yoshita K; Nishi N
    Nihon Koshu Eisei Zasshi; 2021 Sep; 68(9):631-643. PubMed ID: 34261839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential effect of salt reduction in processed foods on health.
    Hendriksen MA; Hoogenveen RT; Hoekstra J; Geleijnse JM; Boshuizen HC; van Raaij JM
    Am J Clin Nutr; 2014 Mar; 99(3):446-53. PubMed ID: 24335058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the health and economic effects of the proposed US Food and Drug Administration voluntary sodium reformulation: Microsimulation cost-effectiveness analysis.
    Pearson-Stuttard J; Kypridemos C; Collins B; Mozaffarian D; Huang Y; Bandosz P; Capewell S; Whitsel L; Wilde P; O'Flaherty M; Micha R
    PLoS Med; 2018 Apr; 15(4):e1002551. PubMed ID: 29634725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina.
    Augustovski F; Chaparro M; Palacios A; Shi L; Beratarrechea A; Irazola V; Rubinstein A; Mills K; He J; Pichon Riviere A
    Value Health; 2018 Dec; 21(12):1357-1364. PubMed ID: 30502778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing salt intake in the Americas: Pan American Health Organization actions.
    Legetic B; Campbell N
    J Health Commun; 2011 Aug; 16 Suppl 2():37-48. PubMed ID: 21916712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina.
    Rubinstein A; Colantonio L; Bardach A; Caporale J; Martí SG; Kopitowski K; Alcaraz A; Gibbons L; Augustovski F; Pichón-Rivière A
    BMC Public Health; 2010 Oct; 10():627. PubMed ID: 20961456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of salt reduction to prevent hypertension and CVD: a systematic review.
    Schorling E; Niebuhr D; Kroke A
    Public Health Nutr; 2017 Aug; 20(11):1993-2003. PubMed ID: 28487006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How three countries in the Americas are fortifying dietary salt reduction: a north and south perspective.
    Legowski B; Legetic B
    Health Policy; 2011 Sep; 102(1):26-33. PubMed ID: 21764474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of reducing salt intake in the Pacific Islands: protocol for a before and after intervention study.
    Webster J; Snowdon W; Moodie M; Viali S; Schultz J; Bell C; Land MA; Downs S; Christoforou A; Dunford E; Barzi F; Woodward M; Neal B
    BMC Public Health; 2014 Feb; 14():107. PubMed ID: 24495646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Projected impact of a reduction in sugar-sweetened beverage consumption on diabetes and cardiovascular disease in Argentina: A modeling study.
    Salgado MV; Penko J; Fernandez A; Konfino J; Coxson PG; Bibbins-Domingo K; Mejia R
    PLoS Med; 2020 Jul; 17(7):e1003224. PubMed ID: 32722677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: modelling study.
    Marklund M; Singh G; Greer R; Cudhea F; Matsushita K; Micha R; Brady T; Zhao D; Huang L; Tian M; Cobb L; Neal B; Appel LJ; Mozaffarian D; Wu JHY
    BMJ; 2020 Apr; 369():m824. PubMed ID: 32321724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of milk powder fortified with potassium to decrease blood pressure and prevent cardiovascular events among the adult population in China: a Markov model.
    Dainelli L; Xu T; Li M; Zimmermann D; Fang H; Wu Y; Detzel P
    BMJ Open; 2017 Sep; 7(9):e017136. PubMed ID: 28951410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting the health impact of lowering salt consumption in Turkey using the DYNAMO health impact assessment tool.
    Erkoyun E; Sözmen K; Bennett K; Unal B; Boshuizen HC
    Public Health; 2016 Nov; 140():228-234. PubMed ID: 27545691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost-effectiveness of government actions to reduce sodium intake through salt substitutes in Vietnam.
    Taylor C; Hoek AC; Deltetto I; Peacock A; Ha DTP; Sieburg M; Hoang D; Trieu K; Cobb LK; Jan S; Webster J
    Arch Public Health; 2021 Mar; 79(1):32. PubMed ID: 33706807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The health, cost and equity impacts of restrictions on the advertisement of high fat, salt and sugar products across the transport for London network: a health economic modelling study.
    Thomas C; Breeze P; Cummins S; Cornelsen L; Yau A; Brennan A
    Int J Behav Nutr Phys Act; 2022 Jul; 19(1):93. PubMed ID: 35897072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of Cardiovascular Events and Related Healthcare Expenditures through Achieving Population-Level Targets of Dietary Salt Intake in Japan: A Simulation Model Based on the National Health and Nutrition Survey.
    Ikeda N; Yamashita H; Hattori J; Kato H; Yoshita K; Nishi N
    Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis.
    Smith-Spangler CM; Juusola JL; Enns EA; Owens DK; Garber AM
    Ann Intern Med; 2010 Apr; 152(8):481-7, W170-3. PubMed ID: 20194225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.
    Murray CJ; Lauer JA; Hutubessy RC; Niessen L; Tomijima N; Rodgers A; Lawes CM; Evans DB
    Lancet; 2003 Mar; 361(9359):717-25. PubMed ID: 12620735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Within trial cost-utility analysis of disease management program for patients hospitalized with atrial fibrillation: results from the SAFETY trial.
    Byrnes J; Ball J; Gao L; Kai Chan Y; Kularatna S; Stewart S; Scuffham PA
    J Med Econ; 2019 Sep; 22(9):945-952. PubMed ID: 31190590
    [No Abstract]   [Full Text] [Related]  

  • 40. The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.
    Penn MS; Yenikomshian MA; Cummings AK; Klemes A; Damron JM; Purvis S; Beidelschies M; Birnbaum HG
    J Med Econ; 2015; 18(7):483-91. PubMed ID: 25763924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.